TG Therapeutics

is a biopharmaceutical company focused on the development of novel, targeted agents for the treatment of various hematologic malignancies and autoimmune disorders.

Product Pipeline

TG-1101 (UBLITUXIMAB)

Ublituximab is a novel, glyco-engineered monoclonal antibody that targets a specific and unique epitope on the B-lymphocyte CD20 antigen, currently in clinical development for hematologic disorders.

TGR-1202

TGR-1202 is an orally available PI3K delta inhibitor targeting the delta isoform with nanomolar potency and several fold selectivity over other PI3K isoforms.

For Investors

NASDAQ: TGTX

Stock Quote at: Jul 22, 4:00PM EDT

Last: $8.26

Change: ($1.34) (13.92%)

Quotes provided by Google - Min 15 minute delay

News & Events

7.21.14

TG Therapeutics' Novel Combination of TG-1101 and TGR-1202 Demonstrates Compelling Early Activity and Safety Profile in Patients With Previously Treated High-Risk Chronic Lymphocytic Leukemia (CLL) and Aggressive Lymphomas

7.21.14

TG Therapeutics, Inc. Announces Second Quarter 2014 Financial Results and Business Update

Product Pipeline

For Investors

News & Events

Quick Links